This is a summary of the European public assessment report (EPAR) for Inductos. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Inductos.
Therapeutic Indication
### Therapeutic indication Inductos is indicated for single level lumbar interbody spine fusion as a substitute for autogenous bone graft in adults with degenerative disc disease who have had at least 6 months of non operative treatment for this condition. Inductos is indicated for the treatment of acute tibia fractures in adults, as an adjunct to standard care using open fracture reduction and intramedullary unreamed nail fixation.
Therapeutic Area (MeSH)
ATC Code
M05BC01
ATC Item
dibotermin alfa
Pharmacotherapeutic Group
Drugs for treatment of bone diseases
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| dibotermin alfa | N/A | Dibotermin alfa |
EMA Name
Inductos
Medicine Name
Inductos
Aliases
N/ANo risk management plan link.
